Takotsubo综合征诊断:基于生物标志物的BioTAK评分
本研究旨在开发并外部验证一种基于生物标志物的诊断评分(BioTAK),以在侵入性冠状动脉造影(ICA)前早期区分Takotsubo综合征(TTS)与急性冠脉综合征(ACS)。研究纳入3615例患者,通过机器学习构建评分,并在独立队列中验证。BioTAK评分在开发队列和验证队列中均表现出优异的区分能力,可帮助早期识别TTS,减少不必要的有创操作。
要点
- BioTAK评分基于5项生物标志物和性别,可早期区分TTS与ACS。
- 使用预设阈值,可在ICA前对近90%患者进行可能诊断分层。
核心结论
- TTS具有与ACS不同的生物标志物特征,BioTAK评分可支持早期识别TTS,简化诊断流程,可能减少疑似ACS患者的不必要有创检查。
研究设计与样本
- 研究纳入3615例来自重叠注册研究的ACS或TTS患者。
- 开发队列1823例(ACS 1754例,TTS 69例),外部验证队列1792例(ACS 1715例,TTS 77例)。
- 使用机器学习引导的特征选择和逻辑回归开发评分,并在独立队列中验证。
主要发现
- 评分包含5项:NT-proBNP、PAM、sLOX-1、LDL-C和性别。
- 使用预设的纳入和排除阈值,评分可在ICA前对近90%患者进行可能诊断分层。
关键数值与推荐
- 开发队列AUC .97,95%CI .95-.98;外部验证AUC .93,95%CI .90-.96。
- 评分项目:NT-proBNP、PAM、sLOX-1、LDL-C和性别(原文无具体阈值和剂量)。
临床怎么用
- 可在ICA前使用BioTAK评分辅助早期诊断TTS,帮助分流患者,减少不必要的有创检查。
局限性
- 原文未报告具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Takotsubo syndrome (TTS) closely mimics acute coronary syndrome (ACS). Early differentiation remains challenging because diagnosis currently relies on medical, psychiatric, and neurological history, repeated cardiac imaging, and exclusion of a culprit epicardial coronary artery lesion, generally with invasive coronary angiography (ICA). The aim of this study was to develop and externally validate a biomarker-based diagnostic score supporting the early differentiation of TTS from ACS before ICA. METHODS: In this study, 3615 patients with ACS or TTS from overlapping registries were investigated. Circulating levels of established and emerging cardiovascular biomarkers were measured before ICA. A biomarker-based diagnostic score for TTS (BioTAK) was developed in a cohort of 1823 patients (ACS n = 1754; TTS n = 69) using machine learning-guided feature selection and logistic regression and externally validated in an independent cohort of 1792 patients (ACS n = 1715; TTS n = 77). RESULTS: The final five-item score incorporated biomarkers reflecting myocardial stress (N-terminal pro-B-type natriuretic peptide), vasoconstriction and anxiety regulation (peptidylglycine α-amidating monooxygenase), atherosclerotic plaque instability (soluble lectin-like oxidized low-density lipoprotein receptor-1), and lipid metabolism (low-density lipoprotein cholesterol), along with sex. BioTAK demonstrated excellent discrimination between TTS and ACS in the development cohort [area under the receiver operating characteristic curve (AUC) .97, 95% confidence interval (CI) .95-.98] and maintained high performance on external validation (AUC .93, 95% CI .90-.96), with good calibration. Using predefined rule-in and rule-out thresholds, the score stratified almost 90% of patients to a likely diagnosis prior to ICA. CONCLUSIONS: TTS is characterized by a distinct biomarker profile reflecting pathophysiological differences from ACS. The non-subjective biomarker-based BioTAK score can support the early identification of TTS, help streamline diagnostic pathways, and might reduce potentially avoidable invasive procedures in patients presenting with suspected ACS. CLINICAL TRIAL REGISTRATION: NCT01000701, NCT01947621.
引用
- Wenzl, Schweiger, Smolle, et al. Takotsubo syndrome diagnosis: the biomarker-based BioTAK score. Eur Heart J. 2026. PMID: 42670759. doi:10.1093/eurheartj/ehag597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。